Search
Now showing items 51-60 of 78
Elemental composition of bone minerals in women with breast cancer treated with adjuvant tamoxifen
(1996)
Oestrogen levels play a major role in conditioning the rates of bone changes in women. Tamoxifen is a synthetic oestrogen antagonist commonly used as an adjuvant therapy for breast cancer. The goal of the present study was ...
Soluble interleukin-2 receptors in patients with advanced colorectal carcinoma
(1996)
The levels of soluble interleukin-2 receptors (sIL-2R) were measured in the serum of 52 patients with advanced colorectal carcinoma and compared to CEA and CA 19-9 levels. Twenty-five normal, age and sex-matched individuals ...
Megestrol acetate in cancer patients with anorexia and weight loss a hellenic co-operative oncology group (heCOG) study
(1993)
Fifty-two patients with hormone-independent cancer, who complained of anorexia and of weight loss with at least 10% received megestrol acetate (MA), 480 mg daily, during 1-21 weeks. of the 41 patients treated during 4 weeks ...
Paclitaxel and gemcitabine in advanced non-nasopharyngeal head and neck cancer: A phase II study conducted by the Hellenic Cooperative Oncology Group
(1999)
Background: Paclitaxel as monotherapy or in combination with other drugs has demonstrated significant activity in patients with squamous cell carcinoma of the head and neck region (SCCHN). Preclinical studies have shown ...
EO9 phase II study in advanced breast, gastric, pancreatic and colorectal carcinoma by the EORTC early clinical studies group
(1996)
In a phase II trial, the activity of EO9, a new bioreductive alkylating agent, was assessed. EO9 was used as second-line chemotherapy in breast cancer patients and as first-line chemotherapy for patients with gastric, ...
Combination chemotherapy with cisplatin-vinblastine in malignant mesothelioma
(1994)
From June 1985 to March 1993, 20 consecutive patients with histologically proven malignant mesothelioma were treated with cisplatin 100 mg/m2 i.v. infusion on day 1 and vinblastine 6 mg/m2 i.v. on day 1 and 8. Treatment ...
New evidence that tamoxifen does not induce osteoporosis: A nuclear activation analysis and absorptiometry study
(1992)
The possibility of increased risk for osteoporosis in breast cancer patients treated with tamoxifen was investigated. 26 patients aged 41-65 years without skeletal metastases were studied. All patients were treated with ...
Neglected cases of papillary and follicular thyroid carcinoma. Occurrence of subcutaneous scalp metastases
(1990)
Three cases, two of follicular and one of papillary thyroid carcinoma are reported. All three patients presented with subcutaneous cystic scalp metastases; they had a long-standing history of thyroid cancer, although two ...
Serum soluble interleukin-2 receptors in epithelial ovarian cancer patients
(1995)
The levels of soluble interleulkin-2 receptors (sIL-R2) were measured in the serum of 52 patients with epithelial ovarian carcinoma as well as in 25 age and sex-matched normal controls. The mean serum level of sIL-2R was ...
High-dose epirubicin as a single agent in the treatment of patients with advanced breast cancer. A Hellenic Co-operative Oncology Group study
(1991)
Fifty-two women with advanced breast cancer were treated with 6 cycles of epirubicin. Even though the study was started with a dose schedule of 110 mg/m2 every 3 weeks, the average treatment interval was 26 days and the ...